Chart-Typ:
Zeitraum:
| WELL Health Technologies Corp.: WELL Health Improves Guidance Based on WELL Canada Achieving $100 Million in Annualized Adjusted EBITDA Run-Rate Ahead of Schedule | WELL has reached its goal of $100 million in annualized Adjusted EBITDA(1) run-rate for WELL Canada, three calendar quarters ahead of schedule, driven by strong organic growth across WELL Clinics... ► Artikel lesen |
| WELL Health Technologies Corp.: WELL Health Announces Appointment of Healthcare Executive Derek Clark as Chief Operating Officer | WELL appoints seasoned healthcare and digital health executive Derek Clark as Chief Operating Officer to support the Company's next phase of operational execution and scale. Mr. Clark brings more... ► Artikel lesen |
| WELL Health Technologies Corp.: WELL Health Announces Approval of Normal Course Issuer Bid | Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or the "Company"), a digital health company focused on positively... ► Artikel lesen |
| WeRide Inc.: WeRide, Uber and AVOMO Bring Robotaxis to Madrid | First joint market entry in Europe, with public operations expected in later this year via the Uber appIn partnership with the Madrid Regional Government
MADRID, June 02, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen |
| Uber Technologies, Inc.: WeRide, Uber, and AVOMO Bring Robotaxis to Madrid |
First joint market entry in Europe, with public operations expected later this year via the Uber app
In partnership with the Madrid Regional Government
WeRide (NASDAQ: WRD, HKEX: 0800)... ► Artikel lesen |
| WeRide Inc.: WeRide and Renault Group Return to Roland-Garros for Third Straight Year with Autonomous Robobus Service | PARIS, May 26, 2026 (GLOBE NEWSWIRE) -- WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, today announced that it will once again deploy its autonomous Robobus at the... ► Artikel lesen |
| Gyre Therapeutics Inc.: Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update | Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted... ► Artikel lesen |
| Gyre Therapeutics Inc.: Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company | Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory... ► Artikel lesen |
| Gyre Therapeutics Inc.: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CRUNCHFISH AB finden Sie auf Wallstreet Online.